



The European Molecular Genetics Quality Network

Certificate of Participation 2019

This is to certify that

St. Elizabeth Cancer Institute

Participated in 2019 in the following European Molecular Genetics Quality Network (EMQN) external quality assessment schemes:

Scheme	Genotyping	Interpretation	Clerical	Result
COLORECTAL CANCER (sporadic)	1.96	2.00	2.00	Satisfactory
DNA SEQUENCING - NGS (v Germline)	2.00			Satisfactory
FAP	2.00	2.00	2.00	Satisfactory
HBOC (Panel Testing)	2.00	1.67	2.00	Satisfactory
LUNG CANCER (NSCLC)	1.98	2.00	2.00	Satisfactory
LYNCH	2.00	2.00	2.00	Satisfactory
MELANOMA	1.96	2.00	2.00	Satisfactory
MEN2	2.00	1.83	2.00	Satisfactory
OVARIAN CANCER (v Somatic)	2.00	2.00	2.00	Satisfactory
VHL	2.00	1.75	2.00	Satisfactory

EMQN is a not for profit organisation which provides external quality assessment schemes for genetic testing laboratories. EMQN is a UKAS accredited provider of EQA services and is based at the Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester, UK.

The laboratory participated in 10 schemes and passed 10 of them. The detailed performance data are given on the Individual Laboratory Report (ILR). When viewing the certificates, you should ensure that 10 schemes are listed.

Key: > Scheme Mean < Scheme Mean Poor performance

NRS: No Results Submitted
WFS: Withdrew From Scheme

Signed by:



Prof. David Barton
EMQN Chairman



Dr. Simon Patton
EMQN Director

EMQN is a not for profit organisation which provides external quality assessment schemes for genetic testing laboratories. EMQN is a UKAS accredited provider of EQA services and is based at the Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester, UK.